Serum Glycan Analysis in Breast Cancer
18 Years
N/A
Female
Breast Cancer
Trial Information
Serum Glycan Analysis in Breast Cancer
OBJECTIVES:
- To profile serum glycan biomarkers in women with metastatic stage IV breast cancer,
healthy controls, and patients with noncancer medical illness.
- To determine whether serial serum glycan biomarkers correlate with response of
metastatic disease to treatment.
OUTLINE: This is a multicenter study.
Blood is collected from patients with metastatic breast cancer, patients with noncancerous
illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by
matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron
resonance mass spectrometry (FT ICR MS) methods.
Blood samples are collected every 3 months for up to 18 months from patients with metastatic
breast cancer. Patients without cancer have a single sample collected.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Patient or participant at the Women's Health Clinic, the Internal Medicine Clinic, or
at the UC Davis Cancer Center, meeting 1 of the following criteria:
- Diagnosis of stage IV metastatic breast cancer, receiving active treatment with
chemotherapy, endocrine therapy, or targeted therapy
- Patients/participants without cancer
- Healthy control being seen for annual exams, meeting the following
criteria:
- No chronic disease
- Not on regular prescribed medications
- Patient without cancer being seen in the Internal Medicine Clinic
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Not pregnant or breast feeding
- No other active cancer
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness
Outcome Time Frame:
up to 18 months
Safety Issue:
No
Principal Investigator
Helen K. Chew, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University of California, Davis
Authority:
United States: Institutional Review Board
Study ID:
CDR0000583066
NCT ID:
NCT00897962
Start Date:
September 2006
Completion Date:
January 2014
Related Keywords:
- Breast Cancer
- stage IV breast cancer
- Breast Neoplasms
Name | Location |
|---|---|
| University of California Davis Cancer Center | Sacramento, California 95817 |
